Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Kidney Neoplasms 2Carcinoma, Renal Cell 2

Interventions

pembrolizumab 85Specimen Handling 79Carboplatin 73Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 54Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35olaparib 34Rituximab 34Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Doxorubicin 27Docetaxel 27Pemetrexed 26Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Has results × belzutifan × Clear all
NCT04195750 2026-05-14

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
755 enrolled 28 charts 1 FDA
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04489771 2025-02-11

MK-6482-013

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
154 enrolled 19 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡